Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study.

Autor: Bavendiek, Udo1 (AUTHOR) bavendiek.udo@mh-hannover.de, Berliner, Dominik1 (AUTHOR), Dávila, Lukas Aguirre2 (AUTHOR), Schwab, Johannes3 (AUTHOR), Maier, Lars4 (AUTHOR), Philipp, Sebastian A.5 (AUTHOR), Rieth, Andreas6 (AUTHOR), Westenfeld, Ralf7 (AUTHOR), Piorkowski, Christopher8 (AUTHOR), Weber, Kristina2 (AUTHOR), Hänselmann, Anja1 (AUTHOR), Oldhafer, Maximiliane1 (AUTHOR), Schallhorn, Sven1 (AUTHOR), von der Leyen, Heiko9 (AUTHOR), Schröder, Christoph10 (AUTHOR), Veltmann, Christian1 (AUTHOR), Störk, Stefan11 (AUTHOR), Böhm, Michael12 (AUTHOR), Koch, Armin2 (AUTHOR), Bauersachs, Johann1 (AUTHOR)
Zdroj: European Journal of Heart Failure. May2019, Vol. 21 Issue 5, p676-684. 9p. 1 Diagram, 2 Charts.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje